Literature DB >> 29460758

New Lineage of Lassa Virus, Togo, 2016.

Shannon L M Whitmer, Thomas Strecker, Daniel Cadar, Hans-Peter Dienes, Kelly Faber, Ketan Patel, Shelley M Brown, William G Davis, John D Klena, Pierre E Rollin, Jonas Schmidt-Chanasit, Elisabeth Fichet-Calvet, Bernd Noack, Petra Emmerich, Toni Rieger, Svenja Wolff, Sarah Katharina Fehling, Markus Eickmann, Jan Philipp Mengel, Tilman Schultze, Torsten Hain, William Ampofo, Kofi Bonney, Juliana Naa Dedei Aryeequaye, Bruce Ribner, Jay B Varkey, Aneesh K Mehta, G Marshall Lyon, Gerrit Kann, Philipp De Leuw, Gundolf Schuettfort, Christoph Stephan, Ulrike Wieland, Jochen W U Fries, Matthias Kochanek, Colleen S Kraft, Timo Wolf, Stuart T Nichol, Stephan Becker, Ute Ströher, Stephan Günther.   

Abstract

We describe a strain of Lassa virus representing a putative new lineage that was isolated from a cluster of human infections with an epidemiologic link to Togo. This finding extends the known range of Lassa virus to Togo.

Entities:  

Keywords:  Lassa fever; Lassa virus; Togo; arenaviruses Old World; viral hemorrhagic fever; viruses

Mesh:

Year:  2018        PMID: 29460758      PMCID: PMC5823357          DOI: 10.3201/eid2403.171905

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Lassa virus is endemic to the West Africa countries of Guinea, Sierra Leone, Liberia, Mali, Côte d’Ivoire, and Nigeria (–). The virus causes Lassa fever, a hemorrhagic disease with a case-fatality rate ≈30% in the current hospital setting in West Africa. So far, 4 lineages of Lassa virus are firmly established: lineages I, II, and III circulate in Nigeria, and lineage IV circulates in Guinea, Sierra Leone, Liberia, Mali, and Côte d’Ivoire (–). Recently, strains from Mali and Côte d’Ivoire were proposed to represent a separate lineage V (). The newly discovered Lassa virus strain Kako from Hylomyscus pamfi rodents trapped in Nigeria is designated lineage VI for the purpose of this article (). Lassa virus has not been previously detected in humans or rodents in Togo; therefore, the virus was not considered endemic to this country. We describe a strain of Lassa virus representing a new lineage that was isolated from a cluster of human infections with an epidemiologic link to Togo (Technical Appendix) (,). The clinical courses of the 3 case-patients and medical and public health interventions are described elsewhere (–). The Lassa virus infections in the index case-patient, secondary case-patient 1, and secondary case-patient 2 were confirmed by laboratory investigations at Bernhard Nocht Institute (Hamburg, Germany); Centers for Disease Control and Prevention (Atlanta, GA, USA); and Philipps University (Marburg, Germany), respectively. The viruses from all 3 patients were isolated in Vero E6 cell culture in the respective Biosafety Level 4 laboratories. Full-length virus sequences were generated directly from clinical specimens, from the isolates, or both using next-generation sequencing technology in combination with Sanger sequencing (sequences deposited into GenBank under accession nos. KU961971, KU961972, LT601601, LT601602, MF990886–MF990889) (Technical Appendix). The sequence from the index case-patient was submitted to GenBank on March 23, 2016, and immediately made publicly available to support the laboratory and public health response in Togo and the other affected countries. The virtually identical viruses from the 3 patients confirmed the transmission chains suggested by the epidemiologic data. Only the virus from secondary case-patient 2 showed differences in coding regions—a deletion of 3 nt and a nucleotide exchange in the polymerase (L) gene—from the viruses in the other 2 case-patients. These differences were confirmed by sequencing the virus in the clinical specimens. Differences among the 3 strains in the highly structured intergenic regions might represent artifacts created by the difficulty in sequencing these regions. The phylogeny was inferred using BEAST2 (https://www.beast2.org/) with nucleotide sequences of full-length nucleoprotein (NP), glycoprotein precursor (GPC), and L and Z genes of the Togo strain in conjunction with representative sequences of Lassa virus and other Old World arenaviruses. The most stable reconstruction was obtained for the L gene with the Togo strain being placed in sister relationship with lineage II (all branches with posterior support values >0.97) (Figure). In the NP- and GPC-based phylogenies, the Togo strain clusters with lineages I and VI (Pinneo and Kako strains); however, the branching order is not well supported (posterior values 0.51–0.86) (Figure). The phylogeny based on the small Z gene further supports a relationship of the Togo strain with lineages I, II, and VI (Technical Appendix Figure 1). The ambiguous position of the Togo strain relative to lineages I, II, and VI is consistent with a recombination analysis showing that most of the L gene sequence is related to lineage II, and NP and GPC comprise sequence stretches mainly related to lineages I and VI (Technical Appendix Figure 2). This mosaic structure might be the result of recombination, reassortment, or both or might have evolved by chance.
Figure

Phylogeny of the Lassa virus strain from Togo, 2016. Phylogenetic trees were inferred using BEAST2 (https://www.beast2.org/) for full-length glycoprotein precursor (A), nucleoprotein (B), and polymerase (C) genes. The analysis included representative Lassa virus strains and other Old World arenaviruses (Technical Appendix). Posterior support values are shown at the branches. Lassa virus lineages are indicated by roman numbers on the right. The branch for Mopeia and Mobala virus is shown schematically and the branches for the remaining Old World arenaviruses have been removed for clarity of presentation. The branches for the Togo strain and most closely related Lassa virus lineages are marked (red, Togo; green, lineage II; blue, lineages I and VI). The origins of the Lassa virus strains are abbreviated as follows: CIV, Côte d’Ivoire; GUI, Guinea; LIB, Liberia; MAL, Mali; NIG, Nigeria; SL, Sierra Leone.

Phylogeny of the Lassa virus strain from Togo, 2016. Phylogenetic trees were inferred using BEAST2 (https://www.beast2.org/) for full-length glycoprotein precursor (A), nucleoprotein (B), and polymerase (C) genes. The analysis included representative Lassa virus strains and other Old World arenaviruses (Technical Appendix). Posterior support values are shown at the branches. Lassa virus lineages are indicated by roman numbers on the right. The branch for Mopeia and Mobala virus is shown schematically and the branches for the remaining Old World arenaviruses have been removed for clarity of presentation. The branches for the Togo strain and most closely related Lassa virus lineages are marked (red, Togo; green, lineage II; blue, lineages I and VI). The origins of the Lassa virus strains are abbreviated as follows: CIV, Côte d’Ivoire; GUI, Guinea; LIB, Liberia; MAL, Mali; NIG, Nigeria; SL, Sierra Leone. The long branch (i.e., large phylogenetic distance) separating the Togo strain from known lineages suggests that it represents a new lineage. Because Lassa virus lineages were originally established on the basis of uncorrected sequence distances (), we used the same method here. The frequency distribution of pairwise amino acid distances in GPC, NP, and L between the Togo strain and all other Lassa virus strains perfectly overlaps with the distribution of distances between Lassa virus lineages I, II, III, IV, and VI indicating that the Togo strain is a separate lineage (Technical Appendix Table 1). However, we noted that the distance between the proposed lineage V and lineage IV rather corresponds to intralineage distances, and therefore, we considered lineage V a subclade of lineage IV in our analysis (Technical Appendix Table 1). We propose that formal recognition of Lassa virus lineages should be decided by the International Committee on Taxonomy of Viruses. In conclusion, sequencing Lassa virus from a cluster of imported infections, with the index case-patient originating from Togo, reveals a new lineage of Lassa virus in West Africa. It seems to be related to lineage II or lineages I/VI, which are all circulating in Nigeria.

Technical Appendix

Additional methods used to detect a new Lassa virus strain, Togo, 2016; uncorrected pairwise amino acid distances among Old World arenaviruses; phylogeny of the Lassa virus Togo strain using Z gene sequences; and analysis of potential recombination and/or reassortment in its evolution.
  8 in total

1.  Genetic diversity among Lassa virus strains.

Authors:  M D Bowen; P E Rollin; T G Ksiazek; H L Hustad; D G Bausch; A H Demby; M D Bajani; C J Peters; S T Nichol
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

2.  Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever.

Authors:  Vanessa N Raabe; Gerrit Kann; Bruce S Ribner; Andres Morales; Jay B Varkey; Aneesh K Mehta; G Marshall Lyon; Sharon Vanairsdale; Kelly Faber; Stephan Becker; Markus Eickmann; Thomas Strecker; Shelley Brown; Ketan Patel; Philipp De Leuw; Gundolf Schuettfort; Christoph Stephan; Holger Rabenau; John D Klena; Pierre E Rollin; Anita McElroy; Ute Ströher; Stuart Nichol; Colleen S Kraft; Timo Wolf
Journal:  Clin Infect Dis       Date:  2017-09-01       Impact factor: 9.079

3.  Detection of Lassa virus, Mali.

Authors:  David Safronetz; Job E Lopez; Nafomon Sogoba; Sékou F Traore'; Sandra J Raffel; Elizabeth R Fischer; Hideki Ebihara; Luis Branco; Robert F Garry; Tom G Schwan; Heinz Feldmann
Journal:  Emerg Infect Dis       Date:  2010-07       Impact factor: 6.883

4.  Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage.

Authors:  John T Manning; Naomi Forrester; Slobodan Paessler
Journal:  Front Microbiol       Date:  2015-10-01       Impact factor: 5.640

5.  Lassa Virus in Multimammate Rats, Côte d'Ivoire, 2013.

Authors:  Leonce Kouadio; Kathrin Nowak; Chantal Akoua-Koffi; Sabrina Weiss; Bernard K Allali; Peter T Witkowski; Detlev H Krüger; Emmanuel Couacy-Hymann; Sébastien Calvignac-Spencer; Fabian H Leendertz
Journal:  Emerg Infect Dis       Date:  2015-08       Impact factor: 6.883

6.  New Hosts of The Lassa Virus.

Authors:  Ayodeji Olayemi; Daniel Cadar; N'Faly Magassouba; Adeoba Obadare; Fode Kourouma; Akinlabi Oyeyiola; Samuel Fasogbon; Joseph Igbokwe; Toni Rieger; Sabrina Bockholt; Hanna Jérôme; Jonas Schmidt-Chanasit; Mutien Garigliany; Stephan Lorenzen; Felix Igbahenah; Jean-Nicolas Fichet; Daniel Ortsega; Sunday Omilabu; Stephan Günther; Elisabeth Fichet-Calvet
Journal:  Sci Rep       Date:  2016-05-03       Impact factor: 4.379

7.  Control measures following a case of imported Lassa fever from Togo, North Rhine Westphalia, Germany, 2016.

Authors:  Clara Lehmann; Matthias Kochanek; Diana Abdulla; Stephan Becker; Boris Böll; Anne Bunte; Daniel Cadar; Arno Dormann; Markus Eickmann; Petra Emmerich; Torsten Feldt; Christina Frank; Jochen Fries; Martin Gabriel; Udo Goetsch; René Gottschalk; Stephan Günther; Michael Hallek; Dieter Häussinger; Christian Herzog; Björn Jensen; Felix Kolibay; Michael Krakau; Georg Langebartels; Toni Rieger; Lars Schaade; Jonas Schmidt-Chanasit; Edgar Schömig; Gundolf Schüttfort; Alexander Shimabukuro-Vornhagen; Michael von Bergwelt-Baildon; Ulrike Wieland; Gerhard Wiesmüller; Timo Wolf; Gerd Fätkenheuer
Journal:  Euro Surveill       Date:  2017-09

8.  Management of a Lassa fever outbreak, Rhineland-Palatinate, Germany, 2016.

Authors:  Lutz Ehlkes; Maja George; Gerhard Samosny; Florian Burckhardt; Manfred Vogt; Stefan Bent; Klaus Jahn; Philipp Zanger
Journal:  Euro Surveill       Date:  2017-09
  8 in total
  33 in total

1.  Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity.

Authors:  Helena Müller; Sarah Katharina Fehling; Jens Dorna; Richard A Urbanowicz; Lisa Oestereich; Yvonne Krebs; Larissa Kolesnikova; Martin Schauflinger; Verena Krähling; N'Faly Magassouba; Elisabeth Fichet-Calvet; Jonathan K Ball; Andreas Kaufmann; Stefan Bauer; Stephan Becker; Veronika von Messling; Thomas Strecker
Journal:  NPJ Vaccines       Date:  2020-08-04       Impact factor: 7.344

2.  Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death.

Authors:  Robert W Cross; Rong Xu; Demetrius Matassov; Stefan Hamm; Theresa E Latham; Cheryl S Gerardi; Rebecca M Nowak; Joan B Geisbert; Ayuko Ota-Setlik; Krystle N Agans; Amara Luckay; Susan E Witko; Lena Soukieh; Daniel J Deer; Chad E Mire; Heinz Feldmann; Christian Happi; Karla A Fenton; John H Eldridge; Thomas W Geisbert
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

3.  Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization.

Authors:  Kathryn M Hastie; Robert W Cross; Stephanie S Harkins; Michelle A Zandonatti; Anatoliy P Koval; Megan L Heinrich; Megan M Rowland; James E Robinson; Thomas W Geisbert; Robert F Garry; Luis M Branco; Erica Ollmann Saphire
Journal:  Cell       Date:  2019-08-08       Impact factor: 66.850

4.  Field evaluation of a Pan-Lassa rapid diagnostic test during the 2018 Nigerian Lassa fever outbreak.

Authors:  Matthew L Boisen; Eghosa Uyigue; John Aiyepada; Katherine J Siddle; Lisa Oestereich; Diana K S Nelson; Duane J Bush; Megan M Rowland; Megan L Heinrich; Philomena Eromon; Adeyemi T Kayode; Ikponmwosa Odia; Donatus I Adomeh; Ekene B Muoebonam; Patience Akhilomen; Grace Okonofua; Blessing Osiemi; Omigie Omoregie; Michael Airende; Jacqueline Agbukor; Solomon Ehikhametalor; Chris Okafi Aire; Sophie Duraffour; Meike Pahlmann; Wiebke Böhm; Kayla G Barnes; Samar Mehta; Mambu Momoh; John Demby Sandi; Augustine Goba; Onikepe A Folarin; Ephraim Ogbaini-Emovan; Danny A Asogun; Ekaete A Tobin; George O Akpede; Sylvanus A Okogbenin; Peter O Okokhere; Donald S Grant; John S Schieffelin; Pardis C Sabeti; Stephan Günther; Christian T Happi; Luis M Branco; Robert F Garry
Journal:  Sci Rep       Date:  2020-05-26       Impact factor: 4.379

5.  Lassa fever in Benin: description of the 2014 and 2016 epidemics and genetic characterization of a new Lassa virus.

Authors:  Anges Yadouleton; Caroline Picard; Toni Rieger; Frederic Loko; Daniel Cadar; Emile Cossi Kouthon; Emmanuel Obolli Job; Honoré Bankolé; Lisa Oestereich; Fernand Gbaguidi; Meike Pahlman; Beate Becker-Ziaja; Alexandra Journeaux; Delphine Pannetier; Stéphane Mély; Stéphanie Mundweiler; Damien Thomas; Leon Kohossi; Raoul Saizonou; Clement Glele Kakaï; Magloire Da Silva; Sonia Kossoubedie; André Lukusa Kakonku; Pierre M'Pelé; Stephan Gunther; Sylvain Baize; Elisabeth Fichet-Calvet
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

6.  Metagenomic sequencing at the epicenter of the Nigeria 2018 Lassa fever outbreak.

Authors:  E Ogbaini-Emovon; S Günther; S Duraffour; L E Kafetzopoulou; S T Pullan; P Lemey; M A Suchard; D U Ehichioya; M Pahlmann; A Thielebein; J Hinzmann; L Oestereich; D M Wozniak; K Efthymiadis; D Schachten; F Koenig; J Matjeschk; S Lorenzen; S Lumley; Y Ighodalo; D I Adomeh; T Olokor; E Omomoh; R Omiunu; J Agbukor; B Ebo; J Aiyepada; P Ebhodaghe; B Osiemi; S Ehikhametalor; P Akhilomen; M Airende; R Esumeh; E Muoebonam; R Giwa; A Ekanem; G Igenegbale; G Odigie; G Okonofua; R Enigbe; J Oyakhilome; E O Yerumoh; I Odia; C Aire; M Okonofua; R Atafo; E Tobin; D Asogun; N Akpede; P O Okokhere; M O Rafiu; K O Iraoyah; C O Iruolagbe; P Akhideno; C Erameh; G Akpede; E Isibor; D Naidoo; R Hewson; J A Hiscox; R Vipond; M W Carroll; C Ihekweazu; P Formenty; S Okogbenin
Journal:  Science       Date:  2019-01-04       Impact factor: 47.728

7.  Identification of Common CD8+ T Cell Epitopes from Lassa Fever Survivors in Nigeria and Sierra Leone.

Authors:  Saori Sakabe; Jessica N Hartnett; Nhi Ngo; Augustine Goba; Mambu Momoh; John Demby Sandi; Lansana Kanneh; Beatrice Cubitt; Selma D Garcia; Brian C Ware; Dylan Kotliar; Refugio Robles-Sikisaka; Karthik Gangavarapu; Luis M Branco; Philomena Eromon; Ikponmwosa Odia; Ephraim Ogbaini-Emovon; Onikepe Folarin; Sylvanus Okogbenin; Peter O Okokhere; Christian Happi; Pardis C Sabeti; Kristian G Andersen; Robert F Garry; Juan Carlos de la Torre; Donald S Grant; John S Schieffelin; Michael B A Oldstone; Brian M Sullivan
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

8.  Population structure of Lassa Mammarenavirus in West Africa.

Authors:  Diego Forni; Manuela Sironi
Journal:  Viruses       Date:  2020-04-13       Impact factor: 5.048

Review 9.  Inter-Lineage Variation of Lassa Virus Glycoprotein Epitopes: A Challenge to Lassa Virus Vaccine Development.

Authors:  Francis Ifedayo Ibukun
Journal:  Viruses       Date:  2020-03-31       Impact factor: 5.048

10.  Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity.

Authors:  Helena Müller; Sarah Katharina Fehling; Jens Dorna; Richard A Urbanowicz; Lisa Oestereich; Yvonne Krebs; Larissa Kolesnikova; Martin Schauflinger; Verena Krähling; N'Faly Magassouba; Elisabeth Fichet-Calvet; Jonathan K Ball; Andreas Kaufmann; Stefan Bauer; Stephan Becker; Veronika von Messling; Thomas Strecker
Journal:  NPJ Vaccines       Date:  2020-08-04       Impact factor: 7.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.